CSIMarket
 


Xeris Biopharma Holdings Inc   (XERS)
Other Ticker:  
 
 

XERS's Revenue Growth by Quarter and Year

Xeris Biopharma Holdings Inc 's Revenue results by quarter and year




XERS Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 44.39 33.14 21.43 7.17
III Quarter September 48.32 29.73 11.06 9.45
II Quarter June 38.01 25.31 8.91 2.03
I Quarter March 33.20 22.07 8.20 1.79
FY   163.92 110.25 49.60 20.44



XERS Revenue fourth quarter 2023 Y/Y Growth Comment
Xeris Biopharma Holdings Inc reported Revenue improvement of 33.95% year on year in the fourth quarter 2023, to $ 44.39 millions, this is lower than Xeris Biopharma Holdings Inc 's recent average Revenue surge of 205.45%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 33 other companies have achieved higher Revenue growth. While Xeris Biopharma Holdings Inc ' s Revenue rise of 33.95% ranks overall at the positon no. 549 in the fourth quarter 2023.




XERS Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 33.95 % 54.64 % 198.88 % 168.54 %
III Quarter September 62.53 % 168.81 % 17.04 % 94400 %
II Quarter June 50.18 % 184.06 % 338.92 % 20200 %
I Quarter March 50.43 % 169.15 % 358.1 % 5866.67 %
FY   48.68 % 122.28 % 142.66 % 651.47 %

Financial Statements
Xeris Biopharma Holdings Inc 's fourth quarter 2023 Revenue $ 44.39 millions XERS's Income Statement
Xeris Biopharma Holdings Inc 's fourth quarter 2022 Revenue $ 33.14 millions Quarterly XERS's Income Statement
New: More XERS's historic Revenue Growth >>


XERS Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -8.13 % 11.47 % 93.76 % -24.13 %
III Quarter September 27.12 % 17.46 % 24.13 % 365.52 %
II Quarter June 14.49 % 14.68 % 8.66 % 13.41 %
I Quarter March 0.18 % 2.99 % 14.37 % -32.96 %
FY (Year on Year)   48.68 % 122.28 % 142.66 % 651.47 %




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #94
Overall #549

Revenue Y/Y Growth Statistics
High Average Low
650.73 % 205.45 % 48.68 %
(Dec 31 2020)   (Dec 31 2023)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #94
Overall #549
Revenue Y/Y Growth Statistics
High Average Low
650.73 % 205.45 % 48.68 %
(Dec 31 2020)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Xeris Biopharma Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
29611.11 % 1585.4 % -81.82 %
(Dec 31 2019)  


XERS's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Xeris Biopharma Holdings Inc reported drop in Revenue sequentially by -8.13% to $ 44.39 millions, from $ 48.32 millions achived a quarter before.

Albeit periodic factors normally fuel IV. Quarter 2023 results, that simply was not sufficient to recover Major Pharmaceutical Preparations's company performance, Caden A. Allen, market consultant said and continued that average quarter on quarter Revenue growth is at 1585.4% for Xeris Biopharma Holdings Inc .

Within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Revenue quarter on quarter growth. While Xeris Biopharma Holdings Inc 's Revenue growth quarter on quarter, overall rank is 1544.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #201
Overall #1544
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #201
Overall #1544
Revenue Q/Q Growth Statistics
High Average Low
29611.11 % 1585.4 % -81.82 %
(Dec 31 2019)  


XERS's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Xeris Biopharma Holdings Inc realized drop in Revenue from the third quarter by -8.13% to $ 44.39 millions, from $ 48.32 millions released in the previous reporting period.

Those cyclical circumstance which normally elevate IV. Quarter 2023 performance, were not able to salvage the IV. Quarter for the Xeris Biopharma Holdings Inc , Caden A. Allen, market consultant said, he detected new headwinds down the road for Xeris Biopharma Holdings Inc and continued that average quarter on quarter Revenue growth is at 1585.4% for Xeris Biopharma Holdings Inc .

Within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Revenue quarter on quarter growth. While Xeris Biopharma Holdings Inc 's Revenue growth quarter on quarter, overall rank is 1544.


Xeris Biopharma Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 163.91 $ 152.67 $ 134.07 $ 121.37 $ 110.25
Y / Y Revenue Growth (TTM) 48.68 % 54.94 % 67.87 % 91.23 % 122.32 %
Year on Year Revenue Growth Overall Ranking # 36 # 145 # 188 # 0 # 70
Seqeuential Revenue Change (TTM) 7.37 % 13.87 % 10.47 % 10.09 % 11.89 %
Seq. Revenue Growth (TTM) Overall Ranking # 549 # 430 # 711 # 0 # 359




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, Xeris Biopharma Holdings Inc 's cumulative twelve months Revenue were $ 164 millions, company would post below average annual Revenue growth of 11.89% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the Xeris Biopharma Holdings Inc 's Revenue growth from the 48.32% growth in Sep 30 2023.

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 36, from total ranking in previous quarter at 145.

Revenue TTM Q/Q Growth Statistics
High Average Low
650.73 %
205.45 %
48.68 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 34
Healthcare Sector # 8
Overall # 36

Revenue TTM Y/Y Growth Statistics
High Average Low
650.73 %
205.45 %
48.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 34
Sector # 94
S&P 500 # 549
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, Xeris Biopharma Holdings Inc 's cumulative twelve months Revenue were $ 164 millions, company would post below average annual Revenue growth of 48.68% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the Xeris Biopharma Holdings Inc 's Revenue growth from the 48.32% growth in Sep 30 2023.

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 36, from total ranking in previous quarter at 145.

Revenue TTM Q/Q Growth Statistics
High Average Low
650.73 %
205.45 %
48.68 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 34
Healthcare Sector # 8
Overall # 36

Revenue TTM Y/Y Growth Statistics
High Average Low
650.73 %
205.45 %
48.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 34
Sector # 94
S&P 500 # 549




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
XERS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for XERS's Competitors
Revenue Growth for Xeris Biopharma Holdings Inc 's Suppliers
Revenue Growth for XERS's Customers

You may also want to know
XERS's Annual Growth Rates XERS's Profitability Ratios XERS's Asset Turnover Ratio XERS's Dividend Growth
XERS's Roe XERS's Valuation Ratios XERS's Financial Strength Ratios XERS's Dividend Payout Ratio
XERS's Roa XERS's Inventory Turnover Ratio XERS's Growth Rates XERS's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Inspiremd Inc 58.66%$ 58.664 millions
Aurinia Pharmaceuticals Inc 58.59%$ 58.590 millions
Bioxcel Therapeutics Inc 57.98%$ 57.983 millions
Tela Bio Inc 53.10%$ 53.102 millions
Theralink Technologies Inc 51.82%$ 51.820 millions
Intra cellular Therapies Inc 50.34%$ 50.336 millions
Adma Biologics Inc 49.43%$ 49.427 millions
Insmed Inc48.27%$ 48.273 millions
Hims and Hers Health Inc 48.15%$ 48.151 millions
Armata Pharmaceuticals Inc 45.39%$ 45.385 millions
G1 Therapeutics Inc 45.10%$ 45.102 millions
Natera inc 43.20%$ 43.200 millions
Shockwave Medical Inc 41.36%$ 41.361 millions
Revance Therapeutics Inc 39.82%$ 39.819 millions
Evolus Inc 39.76%$ 39.759 millions
Ani Pharmaceuticals Inc39.71%$ 39.713 millions
Inspire Medical Systems inc 39.46%$ 39.459 millions
Insulet Corporation37.90%$ 37.896 millions
Foghorn Therapeutics Inc 37.88%$ 37.882 millions
Viemed Healthcare Inc 35.28%$ 35.275 millions
Kiniksa Pharmaceuticals ltd 34.76%$ 34.760 millions
Lantheus Holdings Inc 34.56%$ 34.557 millions
P3 Health Partners Inc 34.33%$ 34.332 millions
Xeris Biopharma Holdings Inc 33.93%$ 33.931 millions
Deciphera Pharmaceuticals Inc 32.88%$ 32.877 millions
Urogen Pharma Ltd 32.54%$ 32.539 millions
Anaptysbio Inc 32.27%$ 32.271 millions
Twist Bioscience Corporation31.81%$ 31.811 millions
Clearpoint Neuro Inc 31.62%$ 31.620 millions
Amicus Therapeutics inc 31.47%$ 31.466 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com